Protective effect of C-reactive protein against the lethality induced by Vibrio vulnificus lipopolysaccharide

Microbiology and Immunology

Volumn 44, Issue 5, 2000, Pages 335-340

  Chae, Mee Ree ^a   Park, Byung Hyun ^a   Kim, Jong Suk ^a   Rho, Hye Won ^a   Park, Jin Woo ^a   Kim, Hyung Rho ^a  

^a Chonbuk National University Medical School   (South Korea)

Author keywords

C reactive protein; Lipopolysaccharide; Tumor necrosis factor ; Vibrio vulnificus

Indexed keywords

ACUTE PHASE PROTEIN; C REACTIVE PROTEIN; GALACTOSAMINE; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA;

ACUTE PHASE RESPONSE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL INFECTION; CELL PROTECTION; CONTROLLED STUDY; IMMOBILIZED CELL; INFECTION RISK; LETHALITY; LIVER TOXICITY; MEDIATOR RELEASE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION; VIBRIO VULNIFICUS; WOUND INFECTION;

ANIMALIA; BACTERIA (MICROORGANISMS); NEGIBACTERIA; VIBRIO VULNIFICUS;

EID: 0034044587     PISSN: 03855600     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1348-0421.2000.tb02503.x     Document Type: Article

References (37)

1. Ahmed, N., Thorley, R., Xia, D., Samols, D., and Webster, R.O. 1996. Transgenic mice expressing rabbit C-reactive protein exhibit diminished chemotactic factor-induced alveolitis. Am. J. Respir. Crit. Care Med. 153: 1141-1147.
2. Bahrani, K.F., and Oliver, J.D. 1991. Electrophoretic analysis of lipopolysaccharide isolated from opaque and translucent colony variants of Vibrio vulnificus using various extraction methods. Microbios 66: 83-93.
3. Ballou, S.P., and Lozanski, G. 1992. Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein. Cytokine 4: 361-368.
4. Baumann, H., and Gauldie, J. 1994. The acute phase response. Immunol. Today 15: 74-80.
5. Beutler, B., and Cerami, A. 1988. Tumor necrosis, cachexia, shock, and inflammation: a common mediator. Annu. Rev. Biochem. 57: 505-518.
6. Blake, P.A., Merson, M.H., Weaver, R.E., Hollis, D.G., and Heublein, P.C. 1979. Disease caused by a marine Vibrio. Clinical characteristics and epidemiology. N. Engl. J. Med. 300: 1-5.
7. Brennt, C.E., Wright, A.C., Dutta, S.K., and Morris, J.G., Jr. 1991. Growth of Vibrio vulnificus in serum from alcoholics: association with high transferrin iron saturation. J. Infect. Dis. 164: 1030-1032.
8. Bucklin, S.E., Lake, P., Logdberg, L., and Morrison, D.C. 1995. Therapeutic efficacy of a polymyxin B-dextran 70 conjugate in experimental model of endotoxemia. Antimicrob. Agents Chemother. 39: 1462-1466.
9. Cermak, J., Key, N.S., Bach, R.R., Balla, J., Jacob, H.S., and Vercellotti, G.M. 1993. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 82: 513-520.
10. Decker, K., and Keppler, D. 1974. Galactosamine hepatitis: key role of the nucleotide deficiency period in the pathogenesis of cell injury and cell death. Rev. Physiol. Biochem. Pharmacol. 71: 77-106.
11. Espat, N.J., Auffenberg, T., Abouhamze, A., Baumhofer, J., Moldawer, L.L., and Howard, R.J. 1996. A role for tumor necrosis factor-alpha in the increased mortality associated with Vibrio vulnificus infection in the presence of hepatic dysfunction. Ann. Surg. 223: 428-433.
12. Filep, J., and Foldes-Filep, E. 1989. Effects of C-reactive protein on human neutrophil granulocytes challenged with N-formyl-methionyl-leucyl-phenylalanine and platelet-activating factor. Life Sci. 44: 517-524.
13. Freudenberg, M.A., and Galanos, C. 1991. Tumor necrosis factor alpha mediates lethal activity of killed gram-negative and gram-positive bacteria in D-galactosamine-treated mice. Infect. Immun. 59: 2110-2115.
14. Gabay, C., and Kushner, I. 1999. Acute-phase proteins and other systemic responses to inflammation. N. Engl. J. Med. 340: 448-454.
15. Galanos, C., Freudenberg, M.A., and Reutter, W. 1979. Galactosamine-induced sensitization to the lethal effects of endotoxin. Proc. Natl. Acad. Sci. U.S.A. 76: 5939-5943.
16. Glauser, M.P., Zanetti, G., Baumgartner, J.D., and Cohen, J. 1991. Septic shock: pathogenesis. Lancet 338: 732-736.
17. Hlady, W.G., and Klontz, K.C. 1996. The epidemiology of Vibrio infections in Florida, 1981-1993. J. Infect. Dis. 173: 1176-1183.
18. Hor, L.I., Chang, T.T., and Wang, S.T. 1999. Survival of Vibrio vulnificus in whole blood from patients with chronic liver diseases: association with phagocytosis by neutrophils and serum ferritin levels. J. Infect. Dis. 179: 275-278.
19. Lehmann, V., Freudenberg, M.A., and Galanos, C. 1987. Lethal toxicity of lipopolysaccharide and tumor necrosis factor in normal and D-galactosamine-treated mice. J. Exp. Med. 165: 657-663.
20. Libert, C., Brouckaert, P., and Fiers, W. 1994. Protection by alpha 1-acid glycoprotein against tumor necrosis factor-induced lethality. J. Exp. Med. 180: 1571-1575.
21. Libert, C., Van Molle, W., Brouckaert, P., and Fiers, W. 1996. Alphal-antitrypsin inhibits the lethal response to TNF in mice. J. Immunol. 157: 5126-5129.
22. Linkous, D.A., and Oliver, J.D. 1999. Pathogenesis of Vibrio vulnificus. FEMS Microbiol. Lett. 174: 207-214.
23. McPherson, V.L., Watts, J.A., Simpson, L.M., and Oliver, J.D. 1991. Physiological effects of the lipopolysaccharide of Vibrio vulnificus on mice and rats. Microbios 67: 141-149.
24. Morley, J.J., and Kushner, I. 1982. Serum C-reactive protein levels in disease. Ann. N.Y. Acad. Sci. 389: 406-418.
25. Park, S.D., Shon, H.S., and Joh, N.J. 1991. Vibrio vulnificus septicemia in Korea: clinical and epidemiologic findings in seventy patients. J. Am. Acad. Dermatol. 24: 397-403.
26. Powell, J.L., Wright, A.C., Wasserman, S.S., Hone, D.M., and Morris, J.G., Jr. 1997. Release of tumor necrosis factor alpha in response to Vibrio vulnificus capsular polysaccharide in in vivo and in vitro models. Infect. Immun. 65: 3713-3718.
27. Rietschel, E.T., Kirikae, T., Schade, F.U., Mamat, U., Schmidt, G., Loppnow, H., Ulmer, A.J., Zahringer, U., Seydel, U., Di Padova, F., et al. 1994. Bacterial endotoxin: molecular relationships of structure to activity and function. FASEB J. 8: 217-225.
28. Sato, T., Tadakuma, N., Ikezaki, N., Hashiguchi, A., and Masuda, K. 1998. Endotoxin removal column containing polymyxin B immobilized fiber is useful for the treatment of the patient with Vibrio vulnificus septicemia. Artif. Organs 22: 705-707.
29. Scuderi, P., Dorr, R.T., Liddil, J.D., Finley, P.R., Meltzer, P., Raitano, A.B., and Rybski, J. 1989. Alpha-globulins suppress human leukocyte tumor necrosis factor secretion. Eur. J. Immunol. 19: 939-942.
30. Sherry, B., and Cerami, A. 1988. Cachectin/tumor necrosis factor exerts endocrine, paracrine, and autocrine control of inflammatory responses. J. Cell Biol. 107: 1269-1277.
31. Steel, D.M., and Whitehead, A.S. 1994. The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A protein. Immunol. Today 15: 81-88.
32. Szalai, A.J., Agrawal, A., Greenhough, T.J., and Volanakis, J.E. 1999. C-reactive protein: structural biology and host defense function. Clin. Chem. Lab. Med. 37: 265-270.
33. Tiegs, G., Wolter, M., and Wendel, A. 1989. Tumor necrosis factor is a terminal mediator in galactosamine/endotoxin-induced hepatitis in mice. Biochem. Pharmacol. 38: 627-631.
34. Tilg, H., Vannier, E., Vachino, G., Dinarello, C.A., and Mier, J.W. 1993. Antiinflammatory properties of hepatic acute phase proteins: preferential induction of interleukin I (IL-1) receptor antagonist over IL-1 beta synthesis by human peripheral blood mononuclear cells. J. Exp. Med. 178: 1629-1636.
35. Wright, A.C., Simpson, L.M., and Oliver, J.D. 1981. Role of iron in the pathogenesis of Vibrio vulnificus infections. Infect. Immun. 34: 503-507.
36. Xia, D., and Samols, D. 1997. Transgenic mice expressing rabbit C-reactive protein are resistant to endotoxemia. Proc. Natl. Acad. Sci. U.S.A. 94: 2575-2580.
37. Zouki, C., Beauchamp, M., Baron, C., and Filep, J.G. 1997. Prevention of in vitro neutrophil adhesion to endothelial cells through shedding of L-selectin by C-reactive protein and peptides derived from C-reactive protein. J. Clin. Invest. 100: 522-529.